Johnson Johnson AbbVie: Paths to Pharma Dominance
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Explore the critical factors to consider when choosing no fee travel cards. Ensure your card fits your travel needs.
24,592 articlesJohnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
A targeted international dividend fund surged 26% over the past year and yields around 3.1%, while broad overseas exp...
Meta Platforms is dialing up AI infrastructure spending, guiding 2026 capex to $125-145 billion after a strong Q1. Th...
Texas Instruments preps for July earnings with a guidance-led breakout in industrial and data-center demand, plus a f...
Sen. JD Vance faulted the Trump administration's handling of Epstein-related documents, calling out missteps in commu...
Jim Cramer signals resilience in the AI-security wave, underscoring a ongoing hunt for the next DeepSeek. Here are fi...
The Roundhill Magnificent Seven ETF has delivered strong gains since its April 2023 start, but a growing concentratio...
A veteran strategist warns that the odds stock market meltdown could jump to 35% this year as oil shocks and sluggish...
Universal Corp misses EPS and swings to a loss in the third quarter, triggering a double-digit stock drop. Analysts f...
Datarails rolls out FinanceOS, an AI-native platform pitched as a financial operating system designed to disrupt its ...
In 2025, 50 donors gave a combined $22.4 billion to charity, up 35% from 2024 inflation-adjusted totals. Bill Gates r...
Tesla stock has slid about 18% from its December peak as deliveries declined and autonomy safety metrics raise questi...